NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 06 February 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Professor Iolo Doull (Vice Chair) Present for all items
3. Annett Blochberger Present for all items
4. Emtiyaz Chowdhury Present for all items
5. Carrie Gardner Present for all items
6. Professor Jonathan Ives Present for all items
7. Stuart Mealing Present for all items
8. Dr Shehla Mohammed Present for all items
9. Sara Payne Present for all items
10. Angharad Shambler Items 5.1 to 5.2.2
11. Professor Ed Wilson Present for all items

NICE staff (key players) present

Lorna Dunning, Associate Director Items 1.1 to 4.2.2

Caron Jones, Health Technology Assessment Adviser Items 1.1 to 4.2.2

Cara Gibbons, Health Technology Assessment Analyst Items 1.1 to 4.2.2

Janet Robertson, Associate Director Items 5.1 to 5.2.2

Kate Moore, Project Manager Items 5.1 to 5.2.2

Nigel Gumbleton, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Vicky Gillis -Elliott, Health Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Hangjian Wu, Newcastle NIHR TAR Team, Newcastle University Items 1.1 to 4.1.3

Stephen Rice, Newcastle NIHR TAR Team, Newcastle University Items 1.1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Isaac Ramos, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Siobhan Burns, Professor of Translational Immunology, Clinical expert, nominated by Pharming Items 1.1 to 4.1.3

Austen Worth, Consultant in Paediatric Immunology, Clinical expert, nominated by NHS England Items 4.1.3 to 4.1.3

Susan Walsh, CEO of Immunodeficiency UK, Patient expert, nominated by Immunodeficiency UK Items 1.1 to 4.1.3

Elizabeth Bruen, Endometriosis Clinical Nurse Specialist, Clinical expert, nominated by Besins Healthcare UK Items 5.1 to 5.1.3

Joanne Hanley, Specialist Advisor, Patient expert, nominated by Endometriosis UK Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Angharad Shambler, Professor Dusko Ilic, Tina Garvey and Dr Natalia Kunst.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 16 January 2025.

### Evaluation of Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130] (ECM2)

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pharming.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-hst10059/documents).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Paul Arundel.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-hst10059) .

### Appraisal of Relugolix–estradiol–norethisterone acetate for treating symptoms of endometriosis [ID3982] (ACM2)

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Gedeon Richter.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10873/documents)
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Paul Arundel.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10873).

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Thursday 13 March 2025 and will start promptly at 9am.